Long term antiviral suppression after treatment for neonatal herpes infection.

Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep (2009) 2.31

Treatment of perinatal viral infections to improve neurologic outcomes. Pediatr Res (2016) 0.75

Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J Virol (2006) 2.97

Influence of prior influenza vaccination on antibody and B-cell responses. PLoS One (2008) 2.83

Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med (2002) 2.73

Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol (2006) 2.67

Primary vaccine failure after 1 dose of varicella vaccine in healthy children. J Infect Dis (2008) 2.37

Varicella-zoster virus infection of human dorsal root ganglia in vivo. Proc Natl Acad Sci U S A (2005) 1.89

Construction of varicella-zoster virus recombinants from parent Oka cosmids and demonstration that ORF65 protein is dispensable for infection of human skin and T cells in the SCID-hu mouse model. J Virol (2003) 1.86

Varicella-zoster virus transfer to skin by T Cells and modulation of viral replication by epidermal cell interferon-alpha. J Exp Med (2004) 1.85

A self-excisable infectious bacterial artificial chromosome clone of varicella-zoster virus allows analysis of the essential tegument protein encoded by ORF9. J Virol (2007) 1.76

T cell-dependent production of IFN-gamma by NK cells in response to influenza A virus. J Clin Invest (2004) 1.56

Varicella-zoster virus ORF63 inhibits apoptosis of primary human neurons. J Virol (2006) 1.54

Tropism of varicella-zoster virus for human tonsillar CD4(+) T lymphocytes that express activation, memory, and skin homing markers. J Virol (2002) 1.53

Varicella-Zoster virus pathogenesis and immunobiology: new concepts emerging from investigations with the SCIDhu mouse model. J Virol (2005) 1.48

Maternal herpes simplex virus antibody avidity and risk of neonatal herpes. Am J Obstet Gynecol (2006) 1.46

The immediate-early 63 protein of Varicella-Zoster virus: analysis of functional domains required for replication in vitro and for T-cell and skin tropism in the SCIDhu model in vivo. J Virol (2004) 1.40

The replication cycle of varicella-zoster virus: analysis of the kinetics of viral protein expression, genome synthesis, and virion assembly at the single-cell level. J Virol (2009) 1.38

Mutational analysis of open reading frames 62 and 71, encoding the varicella-zoster virus immediate-early transactivating protein, IE62, and effects on replication in vitro and in skin xenografts in the SCID-hu mouse in vivo. J Virol (2003) 1.38

The requirement of varicella zoster virus glycoprotein E (gE) for viral replication and effects of glycoprotein I on gE in melanoma cells. Virology (2002) 1.37

Varicella zoster disease of the central nervous system: epidemiological, clinical, and laboratory features 10 years after the introduction of the varicella vaccine. J Infect Dis (2010) 1.36

Microarray analysis of host cell gene transcription in response to varicella-zoster virus infection of human T cells and fibroblasts in vitro and SCIDhu skin xenografts in vivo. J Virol (2003) 1.33

Differentiation of varicella-zoster virus ORF47 protein kinase and IE62 protein binding domains and their contributions to replication in human skin xenografts in the SCID-hu mouse. J Virol (2003) 1.30

Glycoprotein I of varicella-zoster virus is required for viral replication in skin and T cells. J Virol (2002) 1.29

Varicella in the fetus and newborn. Semin Fetal Neonatal Med (2008) 1.29

Humoral and cellular immune responses in children given annual immunization with trivalent inactivated influenza vaccine. Pediatr Infect Dis J (2007) 1.28

Promoter sequences of varicella-zoster virus glycoprotein I targeted by cellular transactivating factors Sp1 and USF determine virulence in skin and T cells in SCIDhu mice in vivo. J Virol (2003) 1.25

Mechanisms of varicella-zoster virus neuropathogenesis in human dorsal root ganglia. J Virol (2008) 1.23

Antiviral CD8 T cells in the control of primary human cytomegalovirus infection in early childhood. J Infect Dis (2004) 1.20

Measles and mumps vaccination as a model to investigate the developing immune system: passive and active immunity during the first year of life. Vaccine (2003) 1.20

Analysis of the frequencies and of the memory T cell phenotypes of human CD8+ T cells specific for influenza A viruses. J Infect Dis (2003) 1.19

A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. J Infect Dis (2006) 1.19

T-cell tropism and the role of ORF66 protein in pathogenesis of varicella-zoster virus infection. J Virol (2005) 1.19

Functions of the C-terminal domain of varicella-zoster virus glycoprotein E in viral replication in vitro and skin and T-cell tropism in vivo. J Virol (2004) 1.17

Signal transducer and activator of transcription 3 (STAT3) and survivin induction by varicella-zoster virus promote replication and skin pathogenesis. Proc Natl Acad Sci U S A (2011) 1.16

Differential requirement for cell fusion and virion formation in the pathogenesis of varicella-zoster virus infection in skin and T cells. J Virol (2004) 1.16

Functions of the ORF9-to-ORF12 gene cluster in varicella-zoster virus replication and in the pathogenesis of skin infection. J Virol (2008) 1.15

Disruption of PML nuclear bodies is mediated by ORF61 SUMO-interacting motifs and required for varicella-zoster virus pathogenesis in skin. PLoS Pathog (2011) 1.14

Functions of Varicella-zoster virus ORF23 capsid protein in viral replication and the pathogenesis of skin infection. J Virol (2008) 1.13

Inhibition of the NF-kappaB pathway by varicella-zoster virus in vitro and in human epidermal cells in vivo. J Virol (2006) 1.12

Phenotypic changes in influenza-specific CD8+ T cells after immunization of children and adults with influenza vaccines. J Infect Dis (2008) 1.12

Baseline levels of influenza-specific CD4 memory T-cells affect T-cell responses to influenza vaccines. PLoS One (2008) 1.11

Entrapment of viral capsids in nuclear PML cages is an intrinsic antiviral host defense against varicella-zoster virus. PLoS Pathog (2011) 1.10

Varicella-zoster virus immediate-early protein 62 blocks interferon regulatory factor 3 (IRF3) phosphorylation at key serine residues: a novel mechanism of IRF3 inhibition among herpesviruses. J Virol (2010) 1.10

Essential functions of the unique N-terminal region of the varicella-zoster virus glycoprotein E ectodomain in viral replication and in the pathogenesis of skin infection. J Virol (2006) 1.10

Analysis of varicella zoster virus attenuation by evaluation of chimeric parent Oka/vaccine Oka recombinant viruses in skin xenografts in the SCIDhu mouse model. Virology (2005) 1.09

Reducing the global burden of congenital rubella syndrome: report of the World Health Organization Steering Committee On Research Related To Measles and Rubella Vaccines and Vaccination, June 2004. J Infect Dis (2005) 1.08

Aberrant infection and persistence of varicella-zoster virus in human dorsal root ganglia in vivo in the absence of glycoprotein I. Proc Natl Acad Sci U S A (2007) 1.07

Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States. J Infect Dis (2004) 1.06

Varicella-zoster virus infection of human neural cells in vivo. Proc Natl Acad Sci U S A (2004) 1.06

Requirement of varicella-zoster virus immediate-early 4 protein for viral replication. J Virol (2003) 1.03

Varicella-zoster virus open reading frame 10 is a virulence determinant in skin cells but not in T cells in vivo. J Virol (2006) 1.03

Structure-function analysis of varicella-zoster virus glycoprotein H identifies domain-specific roles for fusion and skin tropism. Proc Natl Acad Sci U S A (2011) 1.03

Varicella vaccine in the United States: a decade of prevention and the way forward. J Infect Dis (2008) 1.02

Identification of CD8+ T cell epitopes in the immediate early 62 protein (IE62) of varicella-zoster virus, and evaluation of frequency of CD8+ T cell response to IE62, by use of IE62 peptides after varicella vaccination. J Infect Dis (2003) 1.01

Regulation of the ORF61 promoter and ORF61 functions in varicella-zoster virus replication and pathogenesis. J Virol (2009) 1.01

Variability and gender differences in memory T cell immunity to varicella-zoster virus in healthy adults. Vaccine (2006) 1.00

Varicella-zoster virus infection triggers formation of an interleukin-1β (IL-1β)-processing inflammasome complex. J Biol Chem (2011) 0.99

The ubiquitous cellular transcriptional factor USF targets the varicella-zoster virus open reading frame 10 promoter and determines virulence in human skin xenografts in SCIDhu mice in vivo. J Virol (2007) 0.99

ORF66 protein kinase function is required for T-cell tropism of varicella-zoster virus in vivo. J Virol (2006) 0.97

Mutagenesis of varicella-zoster virus glycoprotein B: putative fusion loop residues are essential for viral replication, and the furin cleavage motif contributes to pathogenesis in skin tissue in vivo. J Virol (2009) 0.96

New viral vaccines. Virology (2006) 0.96

3D reconstruction of VZV infected cell nuclei and PML nuclear cages by serial section array scanning electron microscopy and electron tomography. PLoS Pathog (2012) 0.96

Deletion of the first cysteine-rich region of the varicella-zoster virus glycoprotein E ectodomain abolishes the gE and gI interaction and differentially affects cell-cell spread and viral entry. J Virol (2008) 0.95

Cellular and viral factors regulate the varicella-zoster virus gE promoter during viral replication. J Virol (2007) 0.95

Development of recombinant varicella-zoster viruses expressing luciferase fusion proteins for live in vivo imaging in human skin and dorsal root ganglia xenografts. J Virol Methods (2008) 0.95

The attenuated genotype of varicella-zoster virus includes an ORF0 transitional stop codon mutation. J Virol (2012) 0.95

Functions of the unique N-terminal region of glycoprotein E in the pathogenesis of varicella-zoster virus infection. Proc Natl Acad Sci U S A (2009) 0.94

Age-related increase in the frequency of CD4(+) T cells that produce interferon-gamma in response to staphylococcal enterotoxin B during childhood. J Infect Dis (2009) 0.94

Impact of varicella-zoster virus on dendritic cell subsets in human skin during natural infection. J Virol (2010) 0.93

Anti-glycoprotein H antibody impairs the pathogenicity of varicella-zoster virus in skin xenografts in the SCID mouse model. J Virol (2010) 0.92

An immunoreceptor tyrosine-based inhibition motif in varicella-zoster virus glycoprotein B regulates cell fusion and skin pathogenesis. Proc Natl Acad Sci U S A (2013) 0.91

Mutational analysis of the varicella-zoster virus ORF62/63 intergenic region. J Virol (2006) 0.91

Viral and cellular gene transcription in fibroblasts infected with small plaque mutants of varicella-zoster virus. Antiviral Res (2005) 0.90

Latent cytomegalovirus down-regulates major histocompatibility complex class II expression on myeloid progenitors. Blood (2002) 0.90

Induction of cellular and humoral immunity after aerosol or subcutaneous administration of Edmonston-Zagreb measles vaccine as a primary dose to 12-month-old children. J Infect Dis (2004) 0.90

Varicella vaccine. N Engl J Med (2007) 0.89

Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children. Vaccine (2005) 0.89

Effect of maternal herpes simplex virus (HSV) serostatus and HSV type on risk of neonatal herpes. Acta Obstet Gynecol Scand (2007) 0.87

Herpes simplex virus-1 induces expression of a novel MxA isoform that enhances viral replication. Immunol Cell Biol (2010) 0.85

Role of the varicella-zoster virus gene product encoded by open reading frame 35 in viral replication in vitro and in differentiated human skin and T cells in vivo. J Virol (2005) 0.85

Varicella zoster virus ORF25 gene product: an essential hub protein linking encapsidation proteins and the nuclear egress complex. J Proteome Res (2011) 0.84

Immune responses to mumps vaccine in adults who were vaccinated in childhood. J Infect Dis (2008) 0.84

T cell immunity to measles viral proteins in infants and adults after measles immunization. Viral Immunol (2004) 0.84

Mutagenesis of varicella-zoster virus glycoprotein I (gI) identifies a cysteine residue critical for gE/gI heterodimer formation, gI structure, and virulence in skin cells. J Virol (2011) 0.82

Measles humoral and cell-mediated immunity in children aged 5-10 years after primary measles immunization administered at 6 or 9 months of age. J Infect Dis (2013) 0.80

Identification and functional characterization of the Varicella zoster virus ORF11 gene product. Virology (2011) 0.79

One step closer to a CMV vaccine. N Engl J Med (2009) 0.79

Varicella-zoster virus. Preface. Curr Top Microbiol Immunol (2010) 0.78

Effects of interleukin-12 and interleukin-15 on measles-specific T-cell responses in vaccinated infants. Viral Immunol (2008) 0.78

ORF11 protein interacts with the ORF9 essential tegument protein in varicella-zoster virus infection. J Virol (2013) 0.78

Strengthening the nation's influenza vaccination system: a National Vaccine Advisory Committee assessment. Am J Prev Med (2005) 0.77

Identification of a hydrophobic domain in varicella-zoster virus ORF61 necessary for ORF61 self-interaction, viral replication, and skin pathogenesis. J Virol (2013) 0.76

Varicella-zoster virus infection facilitates VZV glycoprotein E trafficking to the membrane surface of melanoma cells. J Med Virol (2003) 0.75

Chickenpox party or varicella vaccine? Adv Exp Med Biol (2005) 0.75